Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05959434 · ClinicalTrials.gov registry record · Phase 2
Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and PTSD
A Phase 2 study of Post Traumatic Stress Disorder and Alcohol Use Disorder, sponsored by Texas A&M University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT05959434: Recruiting Phase 2 study of Post Traumatic Stress Disorder and Alcohol Use Disorder, sponsored by Texas A&M University.
NCT05959434 is a Phase 2 study of Post Traumatic Stress Disorder and Alcohol Use Disorder that is actively recruiting participants, run by Texas A&M University. The registered enrollment target is 200 participants, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (70% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05959434, a Phase 2 study of Post Traumatic Stress Disorder and Alcohol Use Disorder, is actively recruiting participants, sponsored by Texas A&M University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to test the efficacy of a novel integrative cognitive-behavioral intervention in patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD). Specific Aim 1: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing alcohol frequency (percent days drinking) and quantity (drinks per drinking day) as measured by the Timeline Follow-Back (TLFB). Specific Aim 2: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing PTSD symptoms as measured by the Clinician Administered PTSD Scale (CAPS-5). Specific Aim 3: Use ecological momentary assessment (EMA) to evaluate intervention effects on daily alcohol-related cognitions and behaviors through real-time associations with PTSD symptomatology and distress tolerance. Researchers will compare integrative CPT+RP with RP-alone to see if CPT+RP is more efficacious in reducing alcohol use and PTSD symptom severity.
Primary Outcome
Composite of alcohol use frequency (percent days drinking) and quantity (drinks per drinking day), as measured by the Timeline Follow-Back
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Processing Therapy + Relapse Prevention
- BEHAVIORAL Relapse Prevention
Study Locations (2)
South Carolina
- Medical University of South Carolina - Charleston
Texas
- Texas A&M University - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 2 |
What NCT05959434 shows while recruiting
NCT05959434 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Cognitive Processing Therapy + Relapse Prevention is the first listed.
NCT05959434 reports a single indexed study location in South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT05959434 about?
NCT05959434 is a clinical study titled "Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and PTSD". The goal of this clinical trial is to test the efficacy of a novel integrative cognitive-behavioral intervention in patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD). Specific Aim 1: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing alcohol frequen...
What is the current status of trial NCT05959434?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-04-01. Estimated completion is 2028-07-31.
What conditions does trial NCT05959434 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder, Alcohol Use Disorder.
What interventions are being tested in trial NCT05959434?
The interventions under investigation include: Cognitive Processing Therapy + Relapse Prevention (BEHAVIORAL), Relapse Prevention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05959434?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05959434 being conducted?
This trial has 2 study locations across South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05959434's enrollment target sits among peer trials
200 47th of 262 higher than 207 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
RECRUITING · Phase 2
-
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
RECRUITING · Phase 2
-
MDMA for AUD/PTSD Comorbidity
RECRUITING · Phase 2
-
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI